New Real-World Data Supports Use of Antiviral Therapy for Patients Hospitalized With COVID-19
Gilead’s Veklury (remdesivir), a nucleotide analog prodrug, was associated with lower risk of developing long-COVID.
Gilead Sciences has announced new data from three real-world retrospective studies involving its antiviral therapy for patients hospitalized with COVID-19, Veklury (remdesivir), according to a press release.1
To further explore the efficacy of Veklury and its potential impact on the risk of long-COVID, Gilead analyzed HealthVerity data from 52,006 patients. Results from the study showed that Veklury use was associated with a 10% lower risk of any post-COVID conditions (PCC) across multiple age groups.
In the second study, data from the PINC AI Healthcare database from the Omicron era (December 2021 – April 2023) showed an association between Veklury use and reduced mortality among immunocompromised people in the study who were hospitalized for COVID-19. The study included 10,687 immunocompromised patients who received Veklury and 4,989 who were matched controls. At day 28, those who were immunocompromised and treated with Veklury showed an overall 25% lower mortality risk compared to the non-Veklury group.
The third real-world study matched 33,037 patients who received both Veklury and dexamethasone to 33,037 patients who received only dexamethasone. Data showed improved outcomes in those receiving the dual therapy.
“The real-world data presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI) continue to reinforce the strong efficacy and safety profile of Veklury, as well as the potential benefit of Veklury for people affected by COVID-19,” said Frank Duff, MD, senior vice president, virology therapeutic area head, Gilead Sciences in the press release. “As we enter the fourth year of COVID-19, Veklury remains the antiviral standard of care for people hospitalized for COVID-19. These latest data add to our scientific understanding about Veklury’s potential role in reducing mortality, including in immunocompromised people, and helping to reduce the risk of getting long-COVID symptoms.”
Reference
- New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19. News release. March 5, 2024. Accessed March 6, 2024. https://www.gilead.com/news-and-press/press-room/press-releases/2024/3/new-realworld-data-further-support-the-use-of-veklury-remdesivir-for-people-hospitalized-with-covid19
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
